In this interview, Tamer Othman, MD, of City of Hope Orange County’s Lennar Foundation Cancer Center, discusses findings from a real-world analysis evaluating tyrosine kinase inhibitor (TKI) maintenance after treatment with brexucabtagene autoleucel (brexu-cel) in adults with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). This transcript has been edited for clarity.
Tamer Othman
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Tamer
Contact Tamer, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack